Envestnet Portfolio Solutions Inc. Sells 1,647 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Envestnet Portfolio Solutions Inc. lowered its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 67,237 shares of the company’s stock after selling 1,647 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Henry Schein were worth $4,653,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Holocene Advisors LP acquired a new stake in Henry Schein during the third quarter worth approximately $58,319,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Henry Schein during the third quarter worth approximately $43,740,000. Southpoint Capital Advisors LP grew its position in Henry Schein by 30.0% during the third quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock worth $189,540,000 after buying an additional 600,000 shares in the last quarter. Bank of Montreal Can grew its position in Henry Schein by 365.6% during the third quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock worth $52,095,000 after buying an additional 558,689 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Henry Schein during the fourth quarter worth approximately $34,720,000. Institutional investors own 96.62% of the company’s stock.

Wall Street Analysts Forecast Growth

HSIC has been the topic of a number of analyst reports. Mizuho initiated coverage on Henry Schein in a research report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price target on the stock. Wells Fargo & Company initiated coverage on Henry Schein in a research report on Friday, February 14th. They set an “equal weight” rating and a $80.00 price target on the stock. Jefferies Financial Group raised their target price on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Barrington Research reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Henry Schein in a report on Wednesday, February 26th. Finally, UBS Group reduced their target price on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Henry Schein currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.10.

Henry Schein Trading Up 0.3 %

NASDAQ HSIC opened at $72.00 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.49. The company has a market cap of $8.94 billion, a price-to-earnings ratio of 29.63, a price-to-earnings-growth ratio of 2.13 and a beta of 0.90. The business’s fifty day moving average is $74.85 and its 200 day moving average is $72.63.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same period last year, the business earned $0.66 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. As a group, sell-side analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.